251 related articles for article (PubMed ID: 32958051)
21. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
23. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma.
Zhou C; Wang S; Zhou Q; Zhao J; Xia X; Chen W; Zheng Y; Xue M; Yang F; Fu D; Yin Y; Atyah M; Qin L; Zhao Y; Bruns C; Jia H; Ren N; Dong Q
Front Oncol; 2019; 9():1160. PubMed ID: 31781487
[No Abstract] [Full Text] [Related]
24. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer.
Wu M; Li X; Zhang T; Liu Z; Zhao Y
Front Oncol; 2019; 9():996. PubMed ID: 31612115
[No Abstract] [Full Text] [Related]
25. Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data.
Zhou YJ; Zhu GQ; Zhang QW; Zheng KI; Chen JN; Zhang XT; Wang QW; Li XB
DNA Cell Biol; 2019 Nov; 38(11):1207-1222. PubMed ID: 31483163
[TBL] [Abstract][Full Text] [Related]
26. Prognostic signature based on m6A-related lncRNAs to predict overall survival in pancreatic ductal adenocarcinoma.
Wu Q; Chen L; Miao D; Jin Y; Zhu Z
Sci Rep; 2022 Feb; 12(1):3079. PubMed ID: 35197523
[TBL] [Abstract][Full Text] [Related]
27. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma.
Feng Z; Chen P; Li K; Lou J; Wu Y; Li T; Peng C
Front Mol Biosci; 2021; 8():650264. PubMed ID: 34631790
[No Abstract] [Full Text] [Related]
28. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
29. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma.
Feng Z; Li K; Lou J; Wu Y; Peng C
Front Cell Dev Biol; 2021; 9():665161. PubMed ID: 33996821
[TBL] [Abstract][Full Text] [Related]
30. Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
Feng Z; Li K; Wu Y; Peng C
Front Mol Biosci; 2021; 8():659168. PubMed ID: 33834039
[TBL] [Abstract][Full Text] [Related]
31. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
32. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
[TBL] [Abstract][Full Text] [Related]
33. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma.
Curia MC; Fantini F; Lattanzio R; Tavano F; Di Mola F; Piantelli M; Battista P; Di Sebastiano P; Cama A
BMC Cancer; 2019 May; 19(1):452. PubMed ID: 31088413
[TBL] [Abstract][Full Text] [Related]
34. A novel methylation signature predicts inferior outcome of patients with PDAC.
Gu M; Sun J; Zhang S; Chen J; Wang G; Ju S; Wang X
Aging (Albany NY); 2021 Jan; 13(2):2851-2863. PubMed ID: 33550277
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the diagnostic and prognostic value of long non-coding RNA SNHG15 in pancreatic ductal adenocarcinoma.
Guo XB; Yin HS; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5892-5898. PubMed ID: 30280769
[TBL] [Abstract][Full Text] [Related]
36. An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma.
Xiao Z; Li J; Yu Q; Zhou T; Duan J; Yang Z; Liu C; Xu F
Front Pharmacol; 2021; 12():778294. PubMed ID: 35002712
[No Abstract] [Full Text] [Related]
37. Pancreatic ductal adenocarcinoma: a radiomics nomogram outperforms clinical model and TNM staging for survival estimation after curative resection.
Xie T; Wang X; Li M; Tong T; Yu X; Zhou Z
Eur Radiol; 2020 May; 30(5):2513-2524. PubMed ID: 32006171
[TBL] [Abstract][Full Text] [Related]
38. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
39. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
40. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
